318 related articles for article (PubMed ID: 23084763)
1. Immune responses to Clostridium difficile infection.
Madan R; Petri WA
Trends Mol Med; 2012 Nov; 18(11):658-66. PubMed ID: 23084763
[TBL] [Abstract][Full Text] [Related]
2. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.
Frisbee AL; Saleh MM; Young MK; Leslie JL; Simpson ME; Abhyankar MM; Cowardin CA; Ma JZ; Pramoonjago P; Turner SD; Liou AP; Buonomo EL; Petri WA
Nat Commun; 2019 Jun; 10(1):2712. PubMed ID: 31221971
[TBL] [Abstract][Full Text] [Related]
3. The microbiota and immune response during Clostridium difficile infection.
Buonomo EL; Petri WA
Anaerobe; 2016 Oct; 41():79-84. PubMed ID: 27212111
[TBL] [Abstract][Full Text] [Related]
4. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.
Sun X; Hirota SA
Mol Immunol; 2015 Feb; 63(2):193-202. PubMed ID: 25242213
[TBL] [Abstract][Full Text] [Related]
5. Immune responses induced by Clostridium difficile.
Péchiné S; Collignon A
Anaerobe; 2016 Oct; 41():68-78. PubMed ID: 27108093
[TBL] [Abstract][Full Text] [Related]
6. Role of microbiota and innate immunity in recurrent Clostridium difficile infection.
Bibbò S; Lopetuso LR; Ianiro G; Di Rienzo T; Gasbarrini A; Cammarota G
J Immunol Res; 2014; 2014():462740. PubMed ID: 24995345
[TBL] [Abstract][Full Text] [Related]
7. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.
Pawlowski SW; Calabrese G; Kolling GL; Platts-Mills J; Freire R; AlcantaraWarren C; Liu B; Sartor RB; Guerrant RL
J Infect Dis; 2010 Dec; 202(11):1708-12. PubMed ID: 20977342
[TBL] [Abstract][Full Text] [Related]
8. Host recognition of Clostridium difficile and the innate immune response.
Cowardin CA; Petri WA
Anaerobe; 2014 Dec; 30():205-9. PubMed ID: 25223264
[TBL] [Abstract][Full Text] [Related]
9. Novel Chimeric Protein Vaccines Against
Wang S; Wang Y; Cai Y; Kelly CP; Sun X
Front Immunol; 2018; 9():2440. PubMed ID: 30405630
[No Abstract] [Full Text] [Related]
10. Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.
Viladomiu M; Hontecillas R; Pedragosa M; Carbo A; Hoops S; Michalak P; Michalak K; Guerrant RL; Roche JK; Warren CA; Bassaganya-Riera J
PLoS One; 2012; 7(10):e47525. PubMed ID: 23071818
[TBL] [Abstract][Full Text] [Related]
11. Acute infection of mice with Clostridium difficile leads to eIF2α phosphorylation and pro-survival signalling as part of the mucosal inflammatory response.
Sadighi Akha AA; Theriot CM; Erb-Downward JR; McDermott AJ; Falkowski NR; Tyra HM; Rutkowski DT; Young VB; Huffnagle GB
Immunology; 2013 Sep; 140(1):111-22. PubMed ID: 23668260
[TBL] [Abstract][Full Text] [Related]
12. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients.
McFarland LV; Elmer GW; Stamm WE; Mulligan ME
Infect Immun; 1991 Jul; 59(7):2456-62. PubMed ID: 2050409
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.
Jose S; Madan R
Anaerobe; 2016 Oct; 41():85-90. PubMed ID: 27063896
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.
Kim MN; Koh SJ; Kim JM; Im JP; Jung HC; Kim JS
World J Gastroenterol; 2014 Dec; 20(45):17084-91. PubMed ID: 25493020
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
[TBL] [Abstract][Full Text] [Related]
16. John G. Bartlett: Contributions to the discovery of Clostridium difficile antibiotic-associated diarrhea.
Gorbach SL
Clin Infect Dis; 2014 Sep; 59 Suppl 2():S66-70. PubMed ID: 25151480
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis.
Jarchum I; Liu M; Lipuma L; Pamer EG
Infect Immun; 2011 Apr; 79(4):1498-503. PubMed ID: 21245274
[TBL] [Abstract][Full Text] [Related]
18. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
[TBL] [Abstract][Full Text] [Related]
19. Active and passive immunization against Clostridium difficile diarrhea and colitis.
Giannasca PJ; Warny M
Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
[TBL] [Abstract][Full Text] [Related]
20. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.
Nagaro KJ; Phillips ST; Cheknis AK; Sambol SP; Zukowski WE; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2013 Nov; 57(11):5266-70. PubMed ID: 23939887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
